The next immune-checkpoint inhibitors: Pd-1/pd-l1 blockade in melanoma

Clinical Therapeutics

Volumn 37, Issue 4, 2015, Pages 764-782

  Mahoney, Kathleen M ^a,b   Freeman, Gordon J ^b   McDermott, David F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

melanoma; MPDL3280A; nivolumab; PD 1; PD L1; pembrolizumab; pidilizumab; programmed cell death 1

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; CD274 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ANTAGONISTS AND INHIBITORS; HUMAN; IMMUNOTHERAPY; MELANOMA; MULTIMODALITY CANCER THERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84937759727     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.02.018     Document Type: Review

References (91)

1. J.R. Brahmer, C.G. Drake, and I. Wollner Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
2. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
3. O. Hamid, C. Robert, and A. Daud Safety and tumor responses with lambrolizumab (anti-pd-1) in melanoma N Engl J Med 369 2013 134 144
4. S.L. Topalian, M. Sznol, and D.F. McDermott Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 2014 1020 1030
5. J.D. Wolchok, H. Kluger, and M.K. Callahan Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
6. http://seer.cancer.gov/statfacts/html/melan.html. (as of 3/15/2015).
7. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators Lancet 353 1999 14 17
8. S.A. Rosenberg, J.C. Yang, and S.L. Topalian Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 JAMA 271 1994 907 913
9. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
10. D. Schadendorf, F.S. Hodi, and C. Robert Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma J Clin Oncol 2015
11. R.W. Joseph, J.E. Eckel-Passow, and R. Sharma Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2 J Immunother 35 2012 711 715
12. R. Payne, L. Glenn, and H. Hoen Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a community hospital biotherapy program J Immunother Cancer 2 2014 13
13. J.D. Wolchok, A. Hoos, and S. O'Day Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 2009 7412 7420
14. C. Robert, G.V. Long, and B. Brady Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 2015 320 330
15. Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J 11 1992 3887 3895
16. G.J. Freeman Structures of PD-1 with its ligands: sideways and dancing cheek to cheek Proc Natl Acad Sci U S A 105 2008 10275 10276
17. G.J. Freeman, A.J. Long, and Y. Iwai Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
18. Y. Latchman, C.R. Wood, and T. Chernova PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2 2001 261 268
19. N. Rodig, T. Ryan, and J.A. Allen Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis Eur J Immunol 33 2003 3117 3126
20. B.H. Zinselmeyer, S. Heydari, and C. Sacristan PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis J Exp Med 210 2013 757 774
21. T. Honda, J.G. Egen, and T. Lammermann Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues Immunity 40 2014 235 247
22. R. Vibhakar, G. Juan, and F. Traganos Activation-induced expression of human programmed death-1 gene in T-lymphocytes Exp Cell Res 232 1997 25 28
23. A.J. Zajac, J.N. Blattman, and K. Murali-Krishna Viral immune evasion due to persistence of activated T cells without effector function J Exp Med 188 1998 2205 2213
24. R.J. Greenwald, G.J. Freeman, and A.H. Sharpe The B7 family revisited Annu Rev Immunol 23 2005 515 548
25. R. Khattri, J.A. Auger, and M.D. Griffin Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses J Immunol 162 1999 5784 5791
26. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704
27. R.V. Parry, J.M. Chemnitz, and K.A. Frauwirth CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms Mol Cell Biol 25 2005 9543 9553
28. N. Patsoukis, K. Bardhan, and P. Chatterjee PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation Nature Communications 6 2015 6692
29. J. Wang, T. Yoshida, and F. Nakaki Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes Proc Natl Acad Sci U S A 102 2005 11823 11828
30. T. Okazaki, Y. Tanaka, and R. Nishio Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice Nat Med 9 2003 1477 1483
31. H. Nishimura, M. Nose, and H. Hiai Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 11 1999 141 151
32. S. Kasagi, S. Kawano, and T. Okazaki Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice J Immunol 184 2010 2337 2347
33. T.T. Chang, C. Jabs, and R.A. Sobel Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis J Exp Med 190 1999 733 740
34. C. Nielsen, L. Ohm-Laursen, and T. Barington Alternative splice variants of the human PD-1 gene Cell Immunol 235 2005 109 116
35. H. Ueda, J.M. Howson, and L. Esposito Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease Nature 423 2003 506 511
36. B. Wan, H. Nie, and A. Liu Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis J Immunol 177 2006 8844 8850
37. C.L. Day, D.E. Kaufmann, and P. Kiepiela PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression Nature 443 2006 350 354
38. Y. Iwai, S. Terawaki, and M. Ikegawa PD-1 inhibits antiviral immunity at the effector phase in the liver J Exp Med 198 2003 39 50
39. H. Jun, S.K. Seo, and H.Y. Jeong B7-H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK) FEBS Lett 579 2005 6259 6264
40. A.H. Sharpe, E.J. Wherry, R. Ahmed, and G.J. Freeman The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection Nat Immunol 8 2007 239 245
41. P. Smith, C.M. Walsh, and N.E. Mangan Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages J Immunol 173 2004 1240 1248
42. S.C. Liang, R.J. Greenwald, and Y.E. Latchman PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis Eur J Immunol 36 2006 58 64
43. J.A. Brown, D.M. Dorfman, and F.R. Ma Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production J Immunol 170 2003 1257 1266
44. Y. Iwai, M. Ishida, and Y. Tanaka Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci U S A 99 2002 12293 12297
45. Y1 Iwai, S. Terawaki, and T. Honjo PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells Int Immunol 17 2005 133 144
46. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
47. P.A. van der Merwe, D.L. Bodian, and S. Daenke CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics J Exp Med 185 1997 393 403
48. M.J. Butte, M.E. Keir, and T.B. Phamduy Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses Immunity 27 2007 111 122
49. P. Youngnak, Y. Kozono, and H. Kozono Differential binding properties of B7-H1 and B7-DC to programmed death-1 Biochem Biophys Res Commun 307 2003 672 677
50. M.B. Atkins, R.R. Kudchadkar, M. Sznol, R.R. Kudchadkar, and M. Sznol Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma J Clin Oncol 32 5s 2014 (suppl; abstr 9001)
51. R.S. Herbst, J.C. Soria, and M. Kowanetz Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
52. R. Kefford, A. Ribas, and O. Hamid Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475 J Clin Oncol 32 5s 2014 (suppl; abstr 3005)
53. A. Ribas, F.S. Hodi, and R. Kefford Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) J Clin Oncol 32 5s 2014 (suppl; abstr LBA9000^)
54. R. Berger, R. Rotem-Yehudar, and G. Slama Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clin Cancer Res 14 2008 3044 3051
55. P. Armand, A. Nagler, and E.A. Weller Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial J Clin Oncol 31 2013 4199 4206
56. J.R. Westin, F. Chu, and M. Zhang Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial Lancet Oncol 15 2014 69 77
57. C. Wang, K.B. Thudium, and M. Han In vitro characterization of the anti-pd-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates Cancer Immunol Res 2 2014 846 856
58. O. Hamid, J.A. Sosman, and D.P. Lawrence Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM) J Clin Oncol 31 2013 (suppl; abstr 9010)
59. C.Y. Mu, J.A. Huang, and Y. Chen High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Med Oncol 28 2011 682 688
60. R.H. Thompson, M.D. Gillett, and J.C. Cheville Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target Proc Natl Acad Sci U S A 101 2004 17174 17179
61. J. Gadiot, A.I. Hooijkaas, and A.D. Kaiser Overall survival and PD-L1 expression in metastasized malignant melanoma Cancer 117 2011 2192 2201
62. R. Hino, K. Kabashima, and Y. Kato Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma Cancer 116 2010 1757 1766
63. J.M. Taube, R.A. Anders, and G.D. Young Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127ra37
64. M. Gerlinger, A.J. Rowan, and S. Horswell Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
65. J.M. Taube, A.P. Klein, and J.R. Brahmer Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 2014
66. M.R. Green, S. Monti, and S.J. Rodig Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma Blood 116 2010 3268 3277
67. C. Xu, C.M. Fillmore, and S. Koyama Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression Cancer Cell 25 2014 590 604
68. R.H. Thompson, S.M. Kuntz, and B.C. Leibovich Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Res 66 2006 3381 3385
69. T. Powles, J.P. Eder, and G.D. Fine MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562
70. J. Grosso, C.E. Horak, and D. Inzunza Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) J Clin Oncol 31 2013 (suppl; abstr 3016)
71. J.S. Weber, R.R. Kudchadkar, and B. Yu Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma J Clin Oncol 31 2013 4311 4318
72. A.I. Daud, O. Hamid, and A. Ribas Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome AACR Annual Meeting 2014 CT104
73. L. Gandhi, A Balmanoukian, and R. Hui MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression AACR Annual Meeting 2014 CT105
74. T. Seiwert, B. Burtness, and J. Weiss A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer J Clin Oncol 32 5s 2014 (suppl; abstr 6011)
75. J.C. Soria, C. Cruz, and R. Bahleda Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): Additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1) ECCO 2013 Abstract no: 3408
76. T.R. Simpson, F. Li, and W. Montalvo-Ortiz Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma J Exp Med 210 2013 1695 1710
77. M.J. Selby, J.J. Engelhardt, and M. Quigley Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells Cancer Immunol Res 1 2013 32 42
78. M.L. Alegre, P.J. Noel, and B.J. Eisfelder Regulation of surface and intracellular expression of CTLA4 on mouse T cells J Immunol 157 1996 4762 4770
79. C.J. Nirschl, and C.G. Drake Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy Clin Cancer Res 19 2013 4917 4924
80. D.S. Shin, and A. Ribas The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol 33C 2015 23 35
81. Callahan, MK. Understanding the Biology Behind Responses to Immunotherapy. J Clin Oncol. 2014. oral presentation
82. J.D. Powderly, H. Koeppen, and F.S. Hodi Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study J Clin Oncol 31 2013 (suppl; abstr 3001)
83. M.K. Callahan Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab J Clin Oncol 31 2013 (suppl; abstr 3003)
84. M.A. Curran, W. Montalvo, H. Yagita, and J.P. Allison PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proc Natl Acad Sci U S A 107 2010 4275 4280
85. A. Korman, B.J. Chen, and W. Changyu Activity of anti-pd-1 in murine tumor models: role of "host" PD-L1 and synergistic effect of anti-PD-1 and anti-CTLA-4 J Immunol 178 2007 48.37
86. A. Ribas, F.S. Hodi, and M. Callahan Hepatotoxicity with combination of vemurafenib and ipilimumab N Engl J Med 368 2013 1365 1366
87. H. Afrache, P. Gouret, and S. Ainouche The butyrophilin (BTN) gene family: from milk fat to the regulation of the immune response Immunogenetics 64 2012 781 794
88. G.J. Freeman, and A.H. Sharpe A new therapeutic strategy for malaria: targeting T cell exhaustion Nat Immunol 13 2012 113 115
89. Bristol-Myers Squibb. Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared with Dacarbazine; Study Stopped Early. 2014. http://news.bms.com/press-release/phase-3-first-line-melanoma-study-nivolumab-investigational-pd-1-checkpoint-inhibitor-. Accessed February 24, 2015.
90. Postow, MA, Callahan, MK. Wolchok, JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol, 2015 [Epub ahead of print].
91. K.M. Mahoney, and M.B. Atkins Prognostic and predictive markers for the new immunotherapies Oncology (Williston Park) 28 11 suppl 3 2014